




SUPPLEMENTARY FIGURES



Supplementary Figure 1. Fasting GLU levels in control and CLU Tg (ubiquitous OE) male mice. GLU levels in control (littermate non-Tg) and CLU Tg male mice following fasting (n=4 per mouse genotype). Error bars, ± SD; *P<0.05.



Supplementary Figure 2. GLU, INS and PYR decreased tolerance of CLU Tg (pancreas targeted OE) mice, is exacerbated in a model of STZ-mediated induction of diabetes. GLU levels (tolerance curves) in control (Con; littermate non-Tg) mice, control mice being treated with STZ (Con STZ), CLU overexpressing (Tg; pancreas-targeted) mice and CLU overexpressing mice being treated with STZ (Tg STZ). Mice were administered GLU (A₁), INS (B₁) or PYR (C₁); GLU levels were measured before GLU, INS, PYR injection (see, Materials and Methods) and 15, 30, 60 and 120 minutes after. (A₂–C₂) Areas under respective curves (A₁–C₁) being calculated from the sum of the different trapeziums formed (errors bars are shown in curves). (n=5 per mouse genotype). Error bars, ± SD; *P<0.05.



Supplementary Figure 4. CLU OE upregulates proteostatic modules in MEFs derived from TgN102 or TgG106 (ubiquitous OE) mice. (A) Relative *clu* mRNA expression levels in control (Con; littermate non-Tg), TgN102 and TgG106 mice derived MEFs. (B) Relative (%) cathepsin B, L enzymatic activities in control, TgN102 and TgG106 MEFs. (C) Relative (%) proteasome enzymatic activities in control, TgN102 and TgG106 MEFs. Error bars, \pm SD (n=2-4 per mouse genotype); * P <0.05; ** P <0.01.

